Adam D. DeVore

14.9k total citations · 5 hit papers
313 papers, 9.1k citations indexed

About

Adam D. DeVore is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Biomedical Engineering. According to data from OpenAlex, Adam D. DeVore has authored 313 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 224 papers in Cardiology and Cardiovascular Medicine, 89 papers in Surgery and 59 papers in Biomedical Engineering. Recurrent topics in Adam D. DeVore's work include Heart Failure Treatment and Management (183 papers), Cardiovascular Function and Risk Factors (86 papers) and Mechanical Circulatory Support Devices (57 papers). Adam D. DeVore is often cited by papers focused on Heart Failure Treatment and Management (183 papers), Cardiovascular Function and Risk Factors (86 papers) and Mechanical Circulatory Support Devices (57 papers). Adam D. DeVore collaborates with scholars based in United States, Canada and Netherlands. Adam D. DeVore's co-authors include Adrian F. Hernandez, Gregg C. Fonarow, Clyde W. Yancy, Paul A. Heidenreich, Carol I. Duffy, Roland Matsouaka, Deepak L. Bhatt, Robert J. Mentz, Eric J. Velazquez and Javed Butler and has published in prestigious journals such as New England Journal of Medicine, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Adam D. DeVore

295 papers receiving 8.9k citations

Hit Papers

Angiotensin–Neprilysin Inhibition in Acute Decompensated ... 2017 2026 2020 2023 2018 2018 2017 2019 2019 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure
    2018 776 citations Eric J. Velazquez, Adam D. DeVore et al. profile →
  2. Medical Therapy for Heart Failure With Reduced Ejection Fraction
    2018 760 citations Stephen J. Greene, Javed Butler et al. profile →
  3. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction
    2017 705 citations Roland Matsouaka, Deepak L. Bhatt et al. profile →
  4. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction
    2019 303 citations Stephen J. Greene, Gregg C. Fonarow et al. profile →
  5. Heart Failure and Atrial Fibrillation, Like Fire and Fury
    2019 230 citations Marat Fudim, Adam D. DeVore et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adam D. DeVore United States 43 7.1k 1.5k 1.4k 1.3k 998 313 9.1k
Ali Ahmed United States 57 7.6k 1.1× 1.7k 1.2× 1.5k 1.1× 1.1k 0.9× 798 0.8× 369 11.3k
Rita F. Redberg United States 51 5.5k 0.8× 836 0.6× 2.4k 1.7× 1.4k 1.1× 682 0.7× 238 10.0k
Gianluigi Savarese Sweden 44 7.7k 1.1× 1.6k 1.1× 1.5k 1.0× 1.8k 1.4× 694 0.7× 299 10.6k
Ulf Dahlström Sweden 57 8.8k 1.2× 1.5k 1.0× 930 0.6× 1.2k 0.9× 535 0.5× 300 10.9k
Tamara B. Horwich United States 42 6.3k 0.9× 959 0.6× 2.0k 1.4× 1.2k 0.9× 425 0.4× 125 10.7k
Alain Cohen‐Solal France 61 11.0k 1.5× 1.9k 1.3× 1.7k 1.2× 896 0.7× 1.1k 1.1× 250 13.7k
Wendy Gattis Stough United States 40 6.2k 0.9× 1.8k 1.2× 645 0.4× 517 0.4× 602 0.6× 79 7.9k
Anita Deswal United States 54 8.0k 1.1× 1.1k 0.7× 1.5k 1.0× 1.3k 1.0× 422 0.4× 203 11.2k
Peter E. Carson United States 54 16.5k 2.3× 1.4k 1.0× 1.9k 1.3× 1.7k 1.3× 844 0.8× 136 18.2k
Kenneth Dickstein Norway 47 8.7k 1.2× 1.3k 0.9× 1.1k 0.7× 1.1k 0.9× 619 0.6× 166 11.9k

Countries citing papers authored by Adam D. DeVore

Since Specialization
Citations

This map shows the geographic impact of Adam D. DeVore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam D. DeVore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam D. DeVore more than expected).

Fields of papers citing papers by Adam D. DeVore

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam D. DeVore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam D. DeVore. The network helps show where Adam D. DeVore may publish in the future.

Co-authorship network of co-authors of Adam D. DeVore

This figure shows the co-authorship network connecting the top 25 collaborators of Adam D. DeVore. A scholar is included among the top collaborators of Adam D. DeVore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam D. DeVore. Adam D. DeVore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Siddiqi, Tariq Jamal, Harriette G.C. Van Spall, Stephen J. Greene, et al.. (2024). Role of telemedicine in the management of obesity: State‐of‐the‐art review. Obesity Reviews. 25(6). e13734–e13734. 5 indexed citations
2.
Hill, C. Larry, Laine Thomas, Michael E. Nassif, et al.. (2024). Association of Medication Adherence and Health Status in Heart Failure With Reduced Ejection Fraction: Insights From the CHAMP-HF Registry. Circulation Cardiovascular Quality and Outcomes. 17(9). e010211–e010211.
3.
Wilson, Eleanor, Carolyn Glass, Julie M. Steinbrink, et al.. (2024). Kaposi Sarcoma Due to Possible Donor-Derived Human Herpesvirus-8 Infection in a Cardiac Transplant Recipient. The Journal of Heart and Lung Transplantation. 43(4). S455–S455. 2 indexed citations
4.
Farr, Maryjane, Stuart D. Russell, Kelly Schlendorf, et al.. (2023). Beyond Stage C: Considerations in the Management of Patients With Heart Failure Progression and Gaps in Evidence. Journal of Cardiac Failure. 29(5). 818–831.
5.
6.
Lerman, Joseph B, Cynthia L. Green, María Molina, et al.. (2023). Multicenter study of universal prophylaxis versus pre‐emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation. Clinical Transplantation. 37(10). e15065–e15065. 1 indexed citations
7.
Peters, Anthony E., Robert M. Clare, Karen Chiswell, et al.. (2023). Echocardiographic Features Beyond Ejection Fraction and Associated Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. Circulation Heart Failure. 16(5). e010252–e010252. 1 indexed citations
8.
Chaudhry, Sunit‐Preet, Adam D. DeVore, Himabindu Vidula, et al.. (2022). Left Ventricular Assist Devices: A Primer For the General Cardiologist. Journal of the American Heart Association. 11(24). e027251–e027251. 25 indexed citations
9.
Felker, G. Michael, Peter M. Buttrick, Anthony Rosenzweig, et al.. (2022). Heart Failure Strategically Focused Research Network: Summary of Results and Future Directions. Journal of the American Heart Association. 11(18). e025517–e025517. 2 indexed citations
10.
Rao, Vishal N., Anand Shah, Michelle D. Kelsey, et al.. (2022). In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial. Circulation Heart Failure. 16(2). e010158–e010158. 15 indexed citations
11.
Khan, Muhammad Shahzeb, Stephen J. Greene, Anne S. Hellkamp, et al.. (2021). Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. Circulation Heart Failure. 14(11). e008351–e008351. 21 indexed citations
12.
Fonarow, Gregg C., Clyde W. Yancy, Shubin Sheng, et al.. (2021). Regional Variations in Heart Failure Quality and Outcomes: Get With The Guidelines–Heart Failure Registry. Journal of the American Heart Association. 10(7). e018696–e018696. 25 indexed citations
13.
Greene, Stephen J., Javed Butler, Anne S. Hellkamp, et al.. (2021). Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. Journal of Cardiac Failure. 28(3). 370–384. 20 indexed citations
14.
Hess, Paul L., Shubin Sheng, Roland Matsouaka, et al.. (2019). Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines – Heart Failure Program). The American Journal of Cardiology. 125(6). 894–900. 13 indexed citations
15.
Fleming, L., Xin Zhao, Adam D. DeVore, et al.. (2018). Early Ambulation Among Hospitalized Heart Failure Patients Is Associated With Reduced Length of Stay and 30-Day Readmissions. Circulation Heart Failure. 11(4). 25 indexed citations
16.
Sharma, Abhinav, Xin Zhao, Bradley G. Hammill, et al.. (2018). Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure. Circulation Heart Failure. 11(6). e004646–e004646. 129 indexed citations
17.
Fudim, Marat, Kishan S. Parikh, Allison Dunning, et al.. (2018). Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). The American Journal of Cardiology. 122(9). 1506–1512. 12 indexed citations
18.
Vader, Justin, Shane LaRue, Susanna R. Stevens, et al.. (2016). Timing and Causes of Readmission After Acute Heart Failure Hospitalization—Insights From the Heart Failure Network Trials. Journal of Cardiac Failure. 22(11). 875–883. 80 indexed citations
19.
DeVore, Adam D., Vic Hasselblad, Robert J. Mentz, et al.. (2015). Loop Diuretic Dose Adjustments after a Hospitalization for Heart Failure: Insights From ASCEND-HF. European Journal of Heart Failure. 17(3). 340–346. 19 indexed citations
20.
Mentz, Robert J., Mona Fiuzat, Mads Ersbøll, et al.. (2015). Torsemide Versus Furosemide in Heart Failure Patients. Journal of Cardiovascular Pharmacology. 65(5). 438–443. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ali Ahmed Breakdown of academic impact, for papers by Rita F. Redberg Breakdown of academic impact, for papers by Gianluigi Savarese Breakdown of academic impact, for papers by Ulf Dahlström Breakdown of academic impact, for papers by Tamara B. Horwich Breakdown of academic impact, for papers by Alain Cohen‐Solal Breakdown of academic impact, for papers by Wendy Gattis Stough Breakdown of academic impact, for papers by Anita Deswal Breakdown of academic impact, for papers by Peter E. Carson Breakdown of academic impact, for papers by Kenneth Dickstein
Rankless by CCL
2026